| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;115:990-995.)
© 2007 American Heart Association, Inc.
Epidemiology |
From the University of Nottingham, Nottingham, UK.
Correspondence to Dr Andrea Venn, Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Bldg, City Hospital, Nottingham, NG5 1PB, UK. E-mail andrea.venn{at}nottingham.ac.uk
Received June 28, 2006; accepted December 22, 2006.
| Abstract |
|---|
|
|
|---|
Methods and Results We have investigated the cross-sectional relation between secondhand smoke exposure, measured objectively as cotinine, and recognized biomarkers of heart disease risk, namely C-reactive protein, homocysteine, fibrinogen, and white blood cell count, in 7599 never-smoking adults from the Third National Health and Nutrition Examination Survey. Compared with subjects with no detectable cotinine, those with detectable but low-level cotinine (range, 0.05 to 0.215 ng/mL) had significantly higher levels of both fibrinogen (adjusted mean difference, 8.9 mg/dL; 95% CI, 0.9 to 17.0; P=0.03) and homocysteine (0.8 µmol/L; 95% CI, 0.4 to 1.1; P<0.001) but not C-reactive protein or white blood cell count. Effect estimates of similar magnitude and significance were seen in subjects in the high category of cotinine exposure (>0.215 ng/mL). The increased levels of fibrinogen and homocysteine seen in relation to secondhand smoke exposure were equivalent to
30% to 45% of those seen for active smoking.
Conclusions Passive smokers appear to have disproportionately increased levels of 2 biomarkers of cardiovascular disease risk, fibrinogen and homocysteine. This finding provides further evidence to suggest that low-level exposure to secondhand smoke has a clinically important effect on susceptibility to cardiovascular disease.
Key Words: cardiovascular diseases C-reactive protein fibrinogen homocysteine tobacco smoke pollution
| Introduction |
|---|
|
|
|---|
Clinical Perspective p 995
Our present study investigates the association between serum cotinine as an objective measure of SHS exposure and levels of CRP, homocysteine, fibrinogen, and WBC count as biomarkers of cardiovascular disease risk in never-smoking adults participating in the Third National Health and Nutrition Examination Survey (NHANES III).
| Methods |
|---|
|
|
|---|
2 months of age selected for inclusion, questionnaire data were collected on 33 994 (86%) during a home interview. These subjects were then invited to a mobile examination center for a detailed medical examination; 78% (30 818) attended. At this examination, further questionnaires were administered, a variety of tests were performed, and samples of blood (in those
1 year of age) and urine were collected for laboratory analysis. The survey was approved by the Institutional Review Board of the National Center for Health Statistics, and informed consent was obtained before participation.
Blood Measurements
Details of the laboratory analysis of blood samples have been given elsewhere.11 Briefly, serum cotinine was measured by an isotope-dilution high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometric method and had a threshold of detection of 0.05 ng/mL. Serum CRP was measured with latex-enhanced nephelometry and had a threshold of detection of 0.3 mg/dL. Serum homocysteine was measured during phase 2 only with reverse-phase high-performance liquid chromatography and fluorescence detection. Fibrinogen was measured in the plasma of those
40 years of age through the use of a simple enzyme assay. A fully automated hematology analyzer (Coulter Model S-PLUS JR, Coulter Electronics, Hialeah, Fla) was used to provide a quantitative assessment of WBC count. The analytical methods used by each laboratory were consistent with the requirements of the Clinical Laboratory Improvement Act 1988, and rigorous quality control procedures were followed.11 Laboratory staff were blind to the active and passive smoking status of subjects.
Statistical Analysis
For our analysis, only adults
17 years of age (n=20 050) were included; we restricted our analysis to the 9800 who gave a negative response when asked at the home interview whether they had ever smoked at least 100 cigarettes, 20 cigars, or 20 pipes of tobacco in their life. At the mobile examination center examination, participants were further asked about whether they had smoked any cigarettes, cigars, or pipes in the past 5 days; any who responded positively (n=305) were excluded. Of these 9495 adults, 7828 (82%) had serum cotinine data available, and the 7599 with levels
15 ng/mL (consistent with their self-reported nonsmoking status12) were included in subsequent analysis.
Statistical analyses were carried out in STATA version 8.0 (Stata Corp, College Station, Tex) using methods that accounted for the complex sampling design of NHANES III. Biochemical variables were analyzed in the original units provided in the NHANES III data sets. For the exposure variable serum cotinine, many individuals had levels below the threshold of detection; therefore, this variable was categorized for analysis into 3 groups using cut points of 0.05 ng/mL, the threshold level of detection, and 0.215 ng/mL, the median value among those with detectable levels. The groups were labeled no cotinine (<0.05 ng/mL), low cotinine (0.05 to 0.215 ng/mL), and high cotinine (>0.215 ng/mL). The associations between cotinine group and each of the response variables homocysteine, fibrinogen, and WBC count, with adjustment for potential confounders, were assessed using multiple linear regression. Because the response variables homocysteine and WBC count had a small number of high outlying values, model fitting based on both the original and log-transformed values was explored, and because both yielded similar results, those based on the original scale are presented.
For the response variable CRP, a high proportion of individuals had levels below the laboratory threshold of detection of 0.3 mg/dL; therefore, CRP was analyzed as a binary response variable in 2 ways: based on this cut point of 0.3 mg/dL and using a cut point of 1 mg/dL (representing clinically elevated CRP). The association between cotinine group and CRP, again with adjustment for potential confounders, was assessed using multiple logistic regression.
Effect estimates presented are adjusted for the main determinants of cardiovascular health: age, gender, race-ethnicity, social class, physical activity, and body mass index. Race-ethnicity was defined as non-Hispanic white, non-Hispanic black, Mexican American, or other. Social class was measured by the highest year or grade of regular school completed. Physical activity was classified as sedentary, lightly active, moderately active, and vigorously active and was derived from a series of questions asked at the home interview relating to type, intensity, and frequency of different activities and sports. Body mass index was computed by dividing the participants weight, as measured at the mobile examination center examination, by the measured height squared. A number of additional potential confounders were explored and included in the final model only if they altered the magnitude of the effect estimate by
10%. They included diet, alcohol consumption, history of diabetes, waist-to-hip ratio, frequency of aspirin use in the past month, triglycerides, systolic blood pressure, history of hypertension, and ratio of total to high-density lipoprotein cholesterol. Total fruit and vegetable consumption was used as a marker of diet and was derived by summing the number of occasions each month that the participant reported eating a fruit or vegetable. Total meat consumption was computed in a similar manner and was used as an alternative marker of diet. Alcohol consumption was assessed as self-reported total number of times per month that alcohol was consumed. Waist-to-hip ratio was computed as the participants waist circumference divided by the circumference of their buttocks, as measured at the mobile examination center examination. Triglyceride and cholesterol concentrations were quantified from the participants blood sample, and blood pressure was measured at the home interview. For each response variable, evidence of effect modification by age and gender was explored by fitting interaction terms, and stratified results were presented if any interactions were statistically significant (P<0.05).
Our analyses are based on data collected by the US National Center for Health Statistics. Both authors had full access to this data and take full responsibility for the integrity of the data analysis. Both authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
2 test).
|
|
Both the low- and high-cotinine groups had significantly higher levels of fibrinogen and homocysteine than the group with no detectable cotinine (Table 2). These higher levels were of similar magnitude in the low- and high-cotinine groups, with fibrinogen levels estimated to be
9 to 10 mg/dL higher and homocysteine to be 0.8 µmol/L higher in those with compared with those without detectable cotinine. Those with detectable cotinine also had lower WBC, but not significantly so after adjustment for potential confounders (Table 2). There was no evidence that CRP was increased in relation to cotinine (Table 3). Further adjustment for the other potential confounders, including the diet variables (fruit and vegetable consumption and meat consumption), did not materially alter the results. The only exception was WBC count, for which estimates became stronger (ie, more negative) after adjustment for waist-to-hip ratio and weaker (ie, closer to unity) after adjustment for triglycerides. Inclusion of both variables in the model, however, resulted in estimates similar to those in Table 2.
|
|
Restriction of analysis to those
70 years of age with no history of a heart attack, heart failure, or stroke also made little difference to the observed associations. Furthermore, there was no evidence of any effect modification by age or sex.
To put our observed effect estimates for SHS exposure into context, we compared them with those for active smoking by selecting all 4990 current smokers from the NHANES III data set (median cotinine, 208 ng/mL) and computing adjusted mean differences for this active smoking group relative to the same baseline group of never smokers with no detectable cotinine. The adjusted mean difference for fibrinogen was 29.2 mg/dL (compared with 9 to 10 mg/dL in relation to SHS exposure; Table 2) and for homocysteine was 1.8 µmol/L (compared with 0.8 µmol/L in relation to SHS exposure; Table 2).
| Discussion |
|---|
|
|
|---|
The question arises as to whether the elevated levels of these biomarkers seen in passive smokers may be due to some other aspect of our participants lifestyles such as diet. We used self-reported fruit and vegetable consumption as a marker of diet because clinical trials point to this as one of the most influential aspects of diet in terms of cardiovascular health15 and because it is likely to be correlated with other aspects of a healthy diet. In addition, we considered self-reported meat consumption as an alternative marker of diet. Although we cannot completely rule out the possibility of residual confounding, the fact that our associations changed very little after adjustment for these variables and a large number of other lifestyle factors, including physical activity, social class, and obesity, suggests this is unlikely. It is also unlikely that our findings have arisen from selection bias because the overall response for NHANES III was high (86%)10 and the majority of participants (82%) provided a blood sample for which a valid cotinine could be measured. For homocysteine, 11% of our sample (phase 2 only) had a missing value because the homocysteine laboratory analysis was a later addition to the NHANES protocol and carried out in those with sufficient surplus sera; missing data for the other response variables were minimal (<3%).
To minimize the inclusion of misclassified active smokers in our sample, we excluded anyone with a value of serum cotinine >15 ng/mL, the cut point used to distinguish current smokers from nonsmokers,12 and as the Figure shows, the vast majority of our sample had values well below this cut point. Although we can be less confident about the exclusion of misclassified former smokers from our sample, the association between former smoking and fibrinogen and homocysteine in the NHANES III population is relatively weak16; therefore, such misclassification is unlikely to explain our findings.
Our finding of similar-sized effect estimates in the low-cotinine group, of whom only 18% lived with a smoker or were exposed at work, and those with high exposure indicates that even very low levels of exposure may be associated with appreciable increases in cardiovascular risk. Cotinine levels were only
0.1% of those in active smokers, but the apparent effects of passive smoking on the biomarkers we measured were approximately one-third to one-half those for active smoking. These disproportionate associations not only are consistent with the previous studies of fibrinogen6,7 and homocysteine6 but also fit with the epidemiological evidence of a similar disproportionate association with coronary heart disease risk.3,9 Furthermore, they are biologically plausible because both fibrinogen and homocysteine are markers of inflammation and platelet activation, 2 important processes of the cardiovascular system thought to be very sensitive to the toxins in SHS.5 It is likely that multiple mechanisms play a role in the association between SHS and cardiovascular disease, however, including others that we have been unable to consider in this study, and that they interact with each other.5
Meta-analyses of the relation between fibrinogen13 and homocysteine14 and cardiovascular disease risk shed light on the clinical meaningfulness of our findings. They provide strong evidence that these biomarkers are causally related to disease risk and indicate that the magnitude of each of the associations with fibrinogen and homocysteine observed in our study should translate into increases in disease risk of the order of 5%,13,14 although their combined effect is likely to be greater than this. This is lower than the excess risk of 30% estimated from case-control studies using cardiovascular disease as the main outcome,17 perhaps because other mechanisms are playing a role.5
| Conclusions |
|---|
|
|
|---|
| Acknowledgments |
|---|
Disclosures
None.
| References |
|---|
|
|
|---|
2. US Department of Health and Human Services. The Health Consequences of Involuntary Exposure to Tobacco Smoke: A Report by the Surgeon General. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2006.
3. Law MR, Wald NJ. Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis. 2003; 46: 3138.[CrossRef][Medline] [Order article via Infotrieve]
4. Barnoya J, Glantz SA. Secondhand smoke: the evidence of danger keeps growing. Am J Med. 2004; 116: 201202.[CrossRef][Medline] [Order article via Infotrieve]
5. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke: nearly as large as smoking. Circulation. 2005; 111: 26842698.
6. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Masoura C, Toutouzas P, Stefanadis C. Effect of exposure to second hand smoke on inflammation: the ATTICA study. Am J Med. 2004; 116: 145150.[CrossRef][Medline] [Order article via Infotrieve]
7. Iso H, Shimamoto T, Sato S, Koike K, Iida M, Komachi Y. Passive smoking and plasma fibrinogen concentrations. Am J Epidemiol. 1996; 144: 11511154.
8. Stavroulakis GA, Makris TK, Hatzizacharias AN, Tsoukala C, Kyriakidis MK. Passive smoking adversely affects the haemostatis/fibrinolytic parameters in healthy non-smoker offspring of healthy smokers. Thromb Haemost. 2000; 84: 923924.[Medline] [Order article via Infotrieve]
9. Whincup PH, Gilg JA, Emberson JR, Jarvis MJ, Feyerabend C, Bryant A, Walker M, Cook DG. Passive smoking and risk of coronary heart disease and stroke: prospective study with cotinine measurement. BMJ. 2004; 329: 200205.
10. Plan and Operation of the Third National Health and Nutrition Examination Survey, 198894. Hyattsville, Md: National Center for Health Statistics; 1994. Vital and Health Statistics, Series 1: Programs and Collection Procedures, No. 32.
11. Gunter EW, Lewis BG, Koncikowski SM. Laboratory Procedures Used for the Third National Health and Nutrition Examination Survey, 198894. Hyattsville, Md: National Center for Health Statistics; 1996.
12. SRNT Subcommittee on Biochemical Verification. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 2002; 4: 149159.[CrossRef][Medline] [Order article via Infotrieve]
13. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998; 279: 14771482.
14. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002; 325: 12021209.
15. Zarraga IGE, Schwarz ER. Impact of dietary patterns and interventions on cardiovascular health. Circulation. 2006; 114: 961973.
16. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003; 138: 891897.
17. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ. 1997; 315: 973988.
Related Article:
This article has been cited by other articles:
CLINICAL PERSPECTIVE
Secondhand smoke contains the same spectrum of toxins as mainstream smoke and thus is likely to have the same spectrum of harmful effects as active smoking. Because the level of exposure of nonsmokers who live or work with smokers is typically
1% of that of an active smoker, the absolute magnitude of the risk posed by secondhand smoke exposure might be expected to be much lower than that of active smoking. Recent evidence suggests, however, that this may not be the case for cardiovascular disease, for which the risk in nonsmokers exposed to secondhand smoke appears to be
30% of that of active smoking. The present study of the relation between secondhand smoke exposure, measured objectively as serum cotinine, and blood levels of several biological markers of cardiovascular pathology demonstrates that plasma levels of fibrinogen and homocysteine are significantly increased in nonsmokers even with low levels of cotinine in a representative sample of US adults. These findings may suggest a possible mechanism for the finding that very low levels of cigarette smoke have a disproportionately large effect in promoting the pathogenesis of cardiovascular disease. The data provide further evidence that secondhand smoke exposure is an important public health hazard. Policies to protect the public even from modest secondhand smoke exposure are therefore important.
Circulation 2007 115: 945.
![]() |
G. Nagel, F. J. Arnold, M. Wilhelm, B. Link, I. Zoellner, and W. Koenig Environmental tobacco smoke and cardiometabolic risk in young children: results from a survey in south-west Germany Eur. Heart J., August 1, 2009; 30(15): 1885 - 1893. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Benowitz, J. T. Bernert, R. S. Caraballo, D. B. Holiday, and J. Wang Optimal Serum Cotinine Levels for Distinguishing Cigarette Smokers and Nonsmokers Within Different Racial/Ethnic Groups in the United States Between 1999 and 2004 Am. J. Epidemiol., January 15, 2009; 169(2): 236 - 248. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |